Colorado: $10 Million For Cannabis Research

Colorado Will Spend $10 Million Researching Marijuana’s Medical Benefits


There is an abundance of research on marijuana and its benefits, but much of it is anecdotal and fails to pass the muster of the scientific (and government) community. So, when Colorado announced it would be spending $10 million to research medical marijuana, advocates and others alike became understandably excited.

“SB 155 invests the dollars collected from medical marijuana fees into a meaningful effort to study the therapeutic and medical benefits of the drug,” state Rep. Crisanta Duran (D), co-sponsor of the bill that will fund the research. “Patients will benefit from this investment and Colorado will become a national leader in developing medical marijuana research.”

Primarily, the research will be designed to determine which ailments should be approved under the state’s medical marijuana law, in addition to the eight conditions already covered, which include cancer, glaucoma, HIV or AIDS, cachexia (physical wasting with loss of weight and muscle mass), severe pain, severe nausea, seizures (including those characteristic of epilepsy), and persistent muscle spasms (including those characteristic of multiple sclerosis).

Researchers will also study possible negative side-effects of medical marijuana, and “gather objective scientific research regarding the efficacy of administering marijuana and its component parts as part of medical treatment.”

According to Paul Armentano, Deputy Director of the National Organization for the Reform of Marijuana Laws,

“Only one state — California — has previously earmarked state funding to explicitly sponsor clinical cannabis research. That program, established at various universities statewide, funded numerous clinical trials over the past decade evaluating the efficacy of whole-plant cannabis for a variety of conditions, including multiple sclerosis and neuropathic pain.”

The goal in Colorado is to eventually sponsor a series of clinic trials, though it remains to be seen how steadfast (and effective) the Feds will be in stopping that important progress.

The views and opinions expressed in this article are those of the authors/source and do not necessarily reflect the position of CSGLOBE or its staff.

Paid content

What's New Today